Basketball Legend Pau Gasol joins Healthtech Scaleup Idoven in a new round of investment

The company counts global organizations such as AstraZeneca, Abbott, GE Healthcare, FIFPRO, Google, Santander, and Real Madrid Foundation as partners.

Healthtech scale-up Idoven, the leading cardiology-as-a-service platform powered by AI, announces today that the basketball legend Pau Gasol joins Idoven in a new round led by Northzone, with follow-on funding from Insight Partners and major previous investors.

The round will fuel Idoven’s ambition to become the leading global solution for electrocardiogram (ECG) analysis. More specifically, the additional funds will help accelerate the rollout of new solutions using Idoven’s core technology, support healthcare professionals to accurately and efficiently diagnose cardiovascular diseases, and further the company’s geographic expansion. 

Hall of Fame Basketball Star Pau Gasol Joins Idoven in Revolutionizing Heart Health

An Endeavor Spain patron who entered the Basketball Hall of Fame earlier this month, Pau Gasol is a two-time NBA Champion with a 20-year athletic career. Gasol’s investment and involvement in Idoven furthers his commitment to global health and saving lives, as demonstrated by his roles at UNICEF and the Gasol Foundation.

Gasol is the second world-class professional athlete to invest in Idoven, after the Spanish World Cup-winning goalkeeper Iker Casillas joined the company as a seed investor after suffering a heart attack in training at the age of 37.

As a former elite athlete, I know firsthand how important early detection and prevention can be to maintaining optimal health, especially when it comes to cardiovascular issues.

I am thrilled to contribute with my expertise and knowledge, building a strong and successful team culture in a company which has the potential to save thousands of lives, as well as my network and reach to help Idoven scale at such a crucial phase of its growth.

Idoven’s AI technology is completely changing how we measure a healthy heart and prevent and treat heart related disease, something I think will make a big difference.

says Pau Gasol, former professional basketball player, president of Gasol16 Ventures, and Idoven investor. 

Idoven has developed the world’s first cardiology-as-a-service platform powered by artificial intelligence that augments both a cardiologist’s and non-cardiology expert clinician’s ability to identify, triage, and diagnose patients at scale. Idoven is creating a Platform as a Medical Device (PaMD) that analyzes ECGs of any duration from any hardware, reaching cardiologist-level accuracy and with prediction capabilities.

It’s a true honor to count Pau Gasol, a revered global athlete, as an investor at Idoven. In everything we do, we strive to be world class, and we feel that our vision is fully aligned with Gasol’s track record as an athlete and mission as an investor.

His participation in this new funding round couldn’t come at a better time. We’ll be using the investment to double down on product innovation and development, to expand into new markets, and to continue to attract team players among the most talented people we can find across the globe.

adds Manuel Marina Breysse, cardiologist, CEO, and Co-founder of Idoven.

Idoven’s proprietary technology evolved from desktop software created in Madrid in 2018 by two scientists to a cloud-based AI solution used by leading medical device manufacturers and pharmaceutical companies worldwide.

To achieve this growth, Idoven has moved from a closed platform to an open one that can be integrated with third-party hardware, software, electronic medical record systems and pharma companies’ digital solutions.

Idoven is already having a big impact on how cardiovascular health is measured, paving the way for enhanced patient outcomes. While Idoven has grown significantly, there is still a lot to come to deliver the vision of bringing expert-level diagnosis wherever the patient needs it, towards the goal of having a cardiologist in your pocket.

We believe Manuel and his team of medical and AI experts have a chance to build a category-defining company, and we are excited to deepen Northzone commitment with this latest investment.

Michiel Kotting, Partner at Northzone.

Harnessing Innovation: Idoven’s Groundbreaking Approach to Cardiovascular Disease Diagnosis and Prevention

Cardiovascular diseases are still the most prevalent pathologies and the leading cause of death worldwide. Cardiovascular disease costs are estimated to reach $1044 billion worldwide by 2030. 

Cardiovascular disease impacts 32% of global deaths. In the future, validated deep compute will empower providers to touch patients with empathy and accuracy. With Idoven, that future is arriving.

said Scott Barclay, Managing Director atInsight Partners.

Additional investors in this round include venture firm Hambro Perks as well Spring Health co-founder, Adam Chekroud, and Carto CEO, Luis Sanz. Idoven raised a €19.8M Series A round in June 2022, recently partnered with AstraZeneca and received €1.5M in European funding from EIT Health for its early diagnosis of heart attacks project, ASSIST where the company is partnering with leading international hospitals and scientific institutions. 

The company is a member of the MAESTRIA Consortium (H2020), using machine learning to develop the world’s first digital platform for integrative diagnosis of atrial cardiomyopathy and atrial fibrillation to prevent stroke.

The initiative involved collaborating with 17 other leading European and US research centres. Idoven won 1st prize at South Summit in the Most Disruptive & Health verticals category.